Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Dyslipidemia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43873   clinical trials with a EudraCT protocol, of which   7292   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    187 result(s) found for: Dyslipidemia. Displaying page 1 of 10.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2009-017878-21 Sponsor Protocol Number: A3309-005 Start Date*: 2010-02-05
    Sponsor Name:Albireo AB
    Full Title: A Phase IIa, Double-blind, Randomised, Placebo-controlled, Dose-finding Efficacy and Safety Study of A3309 in Patients with Dyslipidemia
    Medical condition: Patients with dyslipidemia but otherwise without symptoms/signs of disease
    Disease: Version SOC Term Classification Code Term Level
    12.1 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2008-004555-30 Sponsor Protocol Number: 1903-004 Start Date*: 2009-04-28
    Sponsor Name:Merck Sharp & Dohme (Sweden) AB
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Lipid-Modifying Effect and Tolerability of MK-1903 in Patients with Dyslipidemia
    Medical condition: Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2004-000775-34 Sponsor Protocol Number: 01-04-TL-475-002 Start Date*: 2004-11-17
    Sponsor Name:Takeda Europe R&D Centre Ltd
    Full Title: A double-blind, randomised, parallel group study to evaluate the safety, tolerability and efficacy of TAK-475 alone or co-administered with atorvastatin in patients with primary dyslipidemia
    Medical condition: Treatment of patients with primary dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    7 10058108 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LT (Completed) CZ (Completed) EE (Completed) SK (Completed) LV (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-000139-27 Sponsor Protocol Number: A509 1018 Start Date*: 2004-09-14
    Sponsor Name:Pfizer AB
    Full Title: A Phase 3, Double-Blind, Placebo-Controlled, Randomized, Parallel Group, Multicenter Study of the Efficacy, Safety, and Tolerability of Fixed Combination Torcetrapib/Atorvastatin Administered Orall...
    Medical condition: Mixed dyslipidemia (Frederickson Types IIa and IIb)
    Disease: Version SOC Term Classification Code Term Level
    10058108
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001934-19 Sponsor Protocol Number: LPS14354 Start Date*: 2016-02-15
    Sponsor Name:Sanofi-Aventis Groupe
    Full Title: A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients with Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Ris...
    Medical condition: Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    18.1 10027433 - Metabolism and nutrition disorders 10058108 Dyslipidaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) DE (Completed) GB (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-000807-33 Sponsor Protocol Number: EFC5823 Start Date*: 2005-05-24
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: Randomized, double-blind, two -arms placebo-controlled, parallel-group, multicenter study of rimonabant 20 mg once daily in the treatment of atherogenic dyslipidemia in abdominally obese patients.
    Medical condition: Abdominally obese patients with atherogenic dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    7.1 10058110 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-002796-35 Sponsor Protocol Number: C4491011 Start Date*: 2021-01-07
    Sponsor Name:Pfizer Inc.
    Full Title: A Phase 2b Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Vupanorsen (PF 07285557) in Statin-Treated Participan...
    Medical condition: dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004861 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2005-006041-16 Sponsor Protocol Number: NK-104-310 Start Date*: 2006-06-30
    Sponsor Name:Kowa Research Europe Ltd.
    Full Title: DOUBLE-BLIND FOLLOW-ON STUDY OF PITAVASTATIN (4 MG) VERSUS ATORVASTATIN (20 MG AND 40 MG), WITH A SINGLE BLIND EXTENSION OF TREATMENT IN PATIENTS WITH TYPE II DIABETES MELLITUS AND COMBINED DYSLIPI...
    Medical condition: Combined Dyslipidemia and Type II Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    8.1 10058110 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-003544-27 Sponsor Protocol Number: PRV-06009 Start Date*: 2006-07-21
    Sponsor Name:Provident Clinical Research & Consulting, Inc.
    Full Title: An Evaluation of Simvastatin 20 mg Plus Omacor 4 g Compared to Simvastatin 20 mg Plus Placebo in Subjects with Mixed Dyslipidemia
    Medical condition: mixed dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002315-25 Sponsor Protocol Number: TAK-475/EC303 Start Date*: 2005-12-15
    Sponsor Name:Takeda Europe R&D Centre Ltd
    Full Title: A double-blind, double dummy, randomized, parallel group, multi-centre Phase III study to evaluate the efficacy and safety of TAK-475 100 mg and TAK-475 100 mg administered in combination with ezet...
    Medical condition: Treatment of patients with primary dyslipidaemia
    Disease: Version SOC Term Classification Code Term Level
    8 10058108 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) EE (Completed) FI (Completed) LV (Completed) LT (Completed) HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-002313-21 Sponsor Protocol Number: TAK-475/EC302 Start Date*: 2005-09-29
    Sponsor Name:Takeda Europe Research & Development Limited
    Full Title: A placebo-controlled, double-blind, randomized study to evaluate the efficacy and safety of TAK-475 50mg and 100mg versus placebo, when co-administered with simvastatin 20mg or 40mg in subjects wit...
    Medical condition: Treatment of patients with primary dyslipidaemia currently taking simvastatin 20mg or 40mg
    Disease: Version SOC Term Classification Code Term Level
    8 10058108 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FI (Completed) EE (Completed) CZ (Completed) DE (Completed) LV (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-002492-14 Sponsor Protocol Number: EFC10139 Start Date*: 2008-03-28
    Sponsor Name:sanofi-aventis recherche & developpement
    Full Title: A randomized, double-blind, parallel-group, multicenter, multinational study to assess the long-term effect, over 1 year, of rimonabant 10 mg in comparison with rimonabant 20 mg after an initial tr...
    Medical condition: Patients with BMI > or = 30 kg/m2 or BMI > 27 kg/m2 with associated risk factors such as Type 2 Diabetes mellitus or Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    10.1 10045260 LLT
    10.1 10058108 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) NL (Prematurely Ended) FI (Completed)
    Trial results: View results
    EudraCT Number: 2014-003213-29 Sponsor Protocol Number: SPh/02/2014 Start Date*: 2015-03-02
    Sponsor Name:SciencePharma spółka z ograniczoną odpowiedzialnością sp. j.
    Full Title: A randomized, multicenter, open-label, two-arm, parallel, phase III study to evaluate the efficacy and safety of nicotinic acid administered in combination with simvastatin for 6 months in comparis...
    Medical condition: Inhibiting the progression of atherosclerosis in patients with carotid arteries stenosis and dyslipidemia.
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029205 - Nervous system disorders 10007687 Carotid artery stenosis PT
    17.1 100000004861 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000536-95 Sponsor Protocol Number: SLx-4090-07-03 Start Date*: 2007-05-08
    Sponsor Name:Surface Logix
    Full Title: A randomised, double-blind, placebo controlled study to evaluate the pharmacodynamics, safety, tolerability and pharmacokinetics profile of SLx-4090 over 14 days dosing in subjects with high trigly...
    Medical condition: Dyslipidemia/hypertriglyceridemia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10058110 Dyslipidemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004735-12 Sponsor Protocol Number: 20130286 Start Date*: 2017-04-06
    Sponsor Name:Amgen Inc
    Full Title: A Double Blind, Randomized, Placebo Controlled, Multicenter Study toEvaluate Safety, Tolerability, and Efficacy on LDL-C of Evolocumab (AMG 145) in Subjects with HIV and with Hyperlipidemia and/or ...
    Medical condition: HIV and hyperlipidemia or mixed dyslipidemia.
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10020604 Hypercholesterolemia LLT
    20.1 100000004861 10020667 Hyperlipidemia LLT
    20.0 100000004848 10020180 HIV positive LLT
    20.0 100000004861 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) PT (Completed) GB (Completed) BE (Completed) ES (Completed) GR (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-002597-30 Sponsor Protocol Number: NIASPAN-DD-2005 Start Date*: 2006-01-02
    Sponsor Name:Gesellschaft für Wissens- und Technologietransfer der TU Dresden mbH
    Full Title: Placebokontrollierte Untersuchung zur Wirkung von Nikotinsäure auf die Dyslipidämie bei Metabolischem Syndrom und das Arterioskleroserisiko
    Medical condition: Dyslipidemia (Hypertriglyzeridemia and/or low HDL-cholersterol) with metabolic syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004686-34 Sponsor Protocol Number: Evaluation Statin Therapy Start Date*: 2007-02-27
    Sponsor Name:Karolinska University Hospital
    Full Title: Evaluation of Statin Therapy- Safety, Effect and Toxicity Mechanisms.
    Medical condition: Frequency of side effects in patients treated with HMG CoA reductase inhibitors.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10058108 Dyslipidaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005924-16 Sponsor Protocol Number: M13-377 Start Date*: 2012-06-13
    Sponsor Name:Abbott Laboratories Ireland Limited
    Full Title: A 12-week, Double-blind, Randomized Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate /Simvastatin 145/20mg and Fenofibrate / Simvastatin 145/40mg Tablets vs. Matching M...
    Medical condition: Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004861 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-001976-75 Sponsor Protocol Number: 20130385 Start Date*: 2014-09-11
    Sponsor Name:Amgen Inc
    Full Title: A Double-Blind, Placebo Controlled, Multicenter Study to Assess the Effect of Evolocumab on Cognitive Function in Patients with Clinically Evident Cardiovascular Disease and Receiving Statin Back...
    Medical condition: Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004861 10020604 Hypercholesterolemia LLT
    17.0 100000004861 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GR (Completed) IT (Completed) FI (Completed) EE (Completed) SK (Completed) LV (Completed) DE (Completed) LT (Completed) CZ (Completed) PT (Completed) BE (Completed) HU (Completed) DK (Completed) ES (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-010198-19 Sponsor Protocol Number: CLCQ908A2204 Start Date*: 2009-05-27
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase 2 12-week multi-center, randomized, double-blind, placebo-controlled, parallel-group adaptive design study to evaluate the safety and efficacy of LCQ for weight reduction and reduced LDL ch...
    Medical condition: Obesity and mixed dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029883 Obesity LLT
    9.1 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) GB (Completed) ES (Completed) DK (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 07 01:30:46 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA